Despite variable clinical trial success with PDE5 inhibitors such as sildenafil and tadalafil and side effects associated with other non-specific PDE inhibitors such as pentoxiphylline (Spinazzola and Kunkel, 2016), our results suggest that PDEs may still be a relevant target for DMD therapeutics. The gene discussed is PDE5A; the disease is Duchenne muscular dystrophy.